UCB S.A.’s Rystiggo has won a US Food and Drug Administration green light to treat two major subtypes of generalized myasthenia gravis (gMG), making it the second human neonatal Fc receptor (FcRn) inhibitor to reach the market just after rival argenx N.V.’s Vyvgart.
UCB’s Rystiggo Becomes Second FcRn Inhibitor Treatment For gMG
Following FDA Approval
The Belgian firm’s Rystiggo may be the second drug of its class to win approval, but a broad label encompassing two major patient groups in generalized myasthenia gravis could set it apart as work starts for a launch later this year.
More from New Products
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
The small interference RNA therapeutic can be used by patients regardless of inhibitor status.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.